Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex ...

Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...

The FDA will decide later this month whether to approve a novel drug for acute pain that could offer a nonaddictive ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Artivion, Inc. AORT: This medical device and tissue ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 7: NextNav ...

Like its competitors, Google continues to experiment with low- and no-code tools that harness agentic AI for business ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

The artificial intelligence (AI) boom has taken the stock market by storm. Wall Street is currently fixated on AI agents, which differ slightly from traditional AI copilots. Alphabet (NASDAQ: GOOGL) ...

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...

TreeFrog Therapeutics is making Cambridgeport Labs the site of its U.S. headquarters, leasing just under 13,500 square feet at the campus. The cell therapy biotech is moving to its own dedicated lab ...

From beauty to fashion, consumer startups are seeking easy debt to expand inventory and facilitate marketing for quick ...